

DMD #20370

Bioactivation of Flutamide Metabolites by Human Liver Microsomes

Ping Kang, Deepak Dalvie, Evan Smith, Sue Zhou, Alan Deese, and James A Nieman

Pharmacokinetics Dynamics and Metabolism (PK, DD, ES, SZ), Analytical Research and
Development (AD)¹, and Medicinal Chemistry (JAN), Pfizer Global Research and
Development, San Diego, CA 92121

DMD #20370

Running Title:

Bioactivation of flutamide metabolites

Corresponding Author:

Ping Kang, Ph.D.

Pharmacokinetics, Dynamics and Metabolism Department,

Pfizer Global Research and Development,

10724 Science Center Drive,

San Diego, CA 92121.

E-mail Address: Ping.Kang@pfizer.com

Phone: (858) 622-7630

Schemes - 5

Table – 1

Figures – 11

References - 36

Number of words

Abstract – 225

Introduction - 648

Discussion – 1475

DMD #20370

d) List of nonstandard abbreviations

Flutamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide; Flu-1, 4-nitro-3-(trifluoromethyl)phenylamine; Flu-2: N-[4-nitro-3-(trifluoromethyl)phenyl]-acetamide; Flu-1-N-OH, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine; Flu-6, 2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]-propanamide GSH, reduced glutathione; ESI, electrospray ionization; LC/MS, liquid chromatography/ mass spectrometry; amu, atomic mass unit.

DMD #20370

Abstract

Flutamide, a widely used nonsteroidal antiandrogen drug for the treatment of prostate cancer, has been associated with rare incidences of hepatotoxicity in patients. It is believed that bioactivation of flutamide and subsequent covalent binding to cellular proteins is responsible for its toxicity. A novel N-S glutathione adduct has been identified in a previous bioactivation study of flutamide (Kang et al, 2007). Due to the extensive first pass metabolism, flutamide metabolites such as 2-hydroxyflutamide and Flu-1 have achieved plasma concentrations higher than the parent in prostate cancer patients. In vitro studies in human liver microsomes were conducted to probe the P450-mediated bioactivation of flutamide metabolites and identify the possible reactive species using reduced glutathione (GSH) as a trapping agent. Several GSH adducts (G1, Flu-1-G1, Flu-1-G2, Flu-6-Gs) derived from the metabolites of flutamide were identified and characterized. A comprehensive bioactivation mechanism was proposed to account for the formation of the observed GSH adducts. Of interest were the formation of a reactive intermediate by the desaturation of the isopropyl group of M5 and the unusual bioactivation of 4-nitro-3-(trifluoromethyl)phenylamine (Flu-1). Studies using recombinant P450s suggested that the major P450 isozymes involved in the bioactivation of flutamide and its metabolites were CYP1A2, CYP3A4, and CYP2C19. These findings suggested that, in addition to the direct bioactivation of flutamide, the metabolites of flutamide could also be bioactivated and contribute to flutamide-induced hepatotoxicity.

DMD #20370

Introduction

Flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide), a widely prescribed nonsteroidal antiandrogen drug, has been shown to increase survival time of prostate cancer patients in combination therapy with luteinizing hormone-releasing agonists or orchiectomy (Brogden and Clissold, 1989; McLeod 1993, Schmitt et. al., 2001). However a number of hepatotoxicity cases were reported to be associated with the clinical use of this drug such as temporary increases in transaminase markers and rare incidences of severe liver dysfunction (Thole et al., 2004, Wysowski and Fourscroy, 1996, Osculati and Castiglioni, 2006, Nakagawa et. al., 1999, Gomez et. al., 1992, Cetin et al., 1999). Several cases of blood eosinophilia have been observed in patients treated with flutamide (Hart and Stricker, 1989), which indicates an immune-mediated mechanism in some patients.

The mechanism of flutamide-induced hepatic dysfunction is currently unknown; however, bioactivation of flutamide has been considered to be the cause of flutamide-induced hepatotoxicity. When metabolically activated by P450s (CYP3A and CYP1A) flutamide has been shown to be covalently bound to microsomal and hepatocyte proteins (Berson et al., 1993, Fau et al., 1994). Ichimura and co-workers have also illustrated the necessity of enhanced flutamide metabolism for development of severe hepatotoxicity (Ichimura et al. 1999). More recently, Matsuzaki and co-workers have demonstrated flutamide-induced toxicity in CYP1A2 knockout SV129 mice administered with 400 mg/kg dose after the mice were fed with an amino acid-deficient diet for 2 weeks, which reduced the glutathione (GSH) content to 27% of initial (Matsuzaki et al. 2006). In vitro conjugation with GSH is widely used in the characterization of reactive metabolites in probing the mechanism of bioactivation (Samuel et al., 2003). Recently a GSH conjugate of hydroxylated flutamide has been detected in human

DMD #20370

liver microsomal and hepatocyte incubations (Soglia et al., 2006; Kostrubsky et al., 2007). Similarly, Tevell and co-workers (Tevell et al., 2006) have detected a mercapturic acid conjugate of hydroxylated flutamide in the urine of prostate cancer patients. In a previous study of the bioactivation of flutamide in human liver microsomes, a novel N-S glutathionyl adduct was detected and fully characterized by MS and NMR, which is formed by the direct bioactivation of the parent drug (Kang et al., 2007).

Due to extensive metabolism of flutamide in the liver, some flutamide metabolites such as 2-hydroxyflutamide and Flu-1 achieved even higher plasma concentrations than the parent in prostate cancer patients. Steady state plasma concentrations of 635 ng/mL and 210 ng/mL have been determined for 2-hydroxyflutamide and Flu-1, respectively, 3 hours post dose in patients with prostate cancer whereas that of flutamide was only 23.6 ng/mL (Aizawa et al., 2003). Thus, it is highly probable that metabolites of flutamide can also be bioactivated and contribute to flutamide-induced hepatotoxicity. Major metabolites of flutamide identified in vitro or in vivo so far are shown in Scheme 1 (Tevell et al., 2006; Goda et al., 2006). In addition to 2-hydroxyflutamide, other oxidative metabolites are monohydroxylated flutamide M5, dihydroxylated flutamide M7, and trihydroxylated flutamide M8. Recently a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine (Flu-1-N-OH), possibly derived from Flu-1, has been identified in the urine of prostate cancer patients and in human liver microsomal incubations (Aizawa et al., 2003; Goda et al., 2006). Additionally, a nitro reduced metabolite 2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]-propanamide (Flu-6) was found in human serum (Katchen and Buxbaum 1975, Takashima et al., 2003). Although studies with flutamide in liver microsomes failed to generate this metabolite, other reductive pathways exist in vivo to produce Flu-6. An acetylated metabolite of Flu-1, N-[4-nitro-3-

DMD #20370

(trifluoromethyl)phenyl]-acetamide (Flu-2), was also reported in the plasma samples of men who were treated with flutamide (Katchen and Buxbaum, 1975).

The present study describes the bioactivation of flutamide metabolites (2-hydroxyflutamide, M5, Flu-1, Flu-2, and Flu-6) in human liver microsomal incubations supplemented with GSH and NADPH. We herein report the detection and characterization of several GSH adducts (G1, Flu-1-G1, Flu-1-G2, Flu-6-G1) derived from the metabolites of flutamide. A comprehensive bioactivation mechanism has been proposed to account for the formation of the observed GSH adducts.

DMD #20370

Materials and Methods

Materials. Flutamide, Flu-1, Flu-2, and glutathione (reduced form, GSH) were purchased from Sigma-Aldrich (St. Louis, MO). Human liver microsomes were prepared from human livers (BD Gentest, Woburn, MA) using standard protocols and were characterized using P450-specific marker substrate activities. Aliquots from the individual preparations from 56 individual human livers were pooled on the basis of equivalent protein concentrations to yield a representative microsomal pool with a protein concentration of 20.4 mg/ml. Recombinant P450 isozymes CYP1A2, CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 supersomes were obtained from BD Gentest (Woburn, MA). All other commercially available reagents and solvents were of either analytical or HPLC grade.

Synthesis of 2-methyl-N-(4-Amino-3-trifluoromethyl-phenyl)-propanamide (Flu-6).

Flutamide (0.505 g, 1.83 mmol) was dissolved in 5 mL methanol. The reaction flask was placed in an oil bath at 55°C and a mixture of sodium sulfide nonahydrate (1.15 g, 4.79 mmol) and sodium bicarbonate (0.355 g, 4.23 mmol) in 5 mL water was added over 5 minutes. The solution began to turn from yellow to orange upon addition of the reducing agent. After addition of approximately 1 mL of the aqueous solution, precipitate began to form. Addition of 15 mL of methanol dissolved most of the precipitate and the reaction mixture was heated in an oil bath at 60°C for 1 h. The reaction appeared to be 50% complete (an aliquot was diluted with methanol and was examined by LC/MS). More of the mixture of sodium sulfide nonahydrate (1.15 g, 4.79 mmol) and sodium bicarbonate (0.355 g, 4.23 mmol) in 5 mL water was added over 3 minutes. After 20 min, water (10 mL) was added and the methanol was removed in vacuo. The remaining aqueous layer was extracted with dichloromethane (DCM) twice. The organic layer was dried over sodium sulfate and concentrated in vacuo producing 419.6 mg of

DMD #20370

a yellow solid. Purification was accomplished by radial chromatography (2 mm plate, DCM to 90 DCM to 10 EtOAc, sample loaded in DCM). The second UV active band produced 90.5 mg of the target compound (20% yield) as a very light yellow solid. LC/MS > 95% (254 nm); ^1H -NMR (400 MHz, MeOD) δ 7.63 (1 H, d, $J = 2.5$ Hz), 7.40 (1 H, dd, $J = 8.8, 2.5$ Hz), 6.79 (1 H, d, $J = 8.8$ Hz), 2.57 (1 H, dt, $J = 13.6, 6.8$ Hz), 1.17 (6 H, d, $J = 6.8$ Hz). ^1H NMR (400 MHz, CDCl₃) δ 7.54 (1 H, d, $J = 2.3$ Hz), 7.46 (1 H, dd, $J = 8.6, 2.3$ Hz), 7.14 (1 H, s), 6.69 (1 H, d, $J = 8.6$ Hz), 4.02 - 4.13 (2 H, m), 2.46 (1 H, dt, $J = 13.7, 6.9$ Hz), 1.23 (6 H, d, $J = 7.1$ Hz). ^{13}C -NMR (100 MHz, CDCl₃) δ 175.4, 142.2, 128.6, 125.9, 124.5 (q, $J = 273$ Hz), 119.0, 117.6, 113.8 (q, $J = 30$ Hz), 36.3, 19.5. HRMS - C₁₁H₁₃N₂OF₃ Theoretical (M+H): 247.10527; Found: 247.10545. Elemental Analysis Theory C, 53.66%; H, 5.32%; F, 23.15%; N, 11.38%; Found C, 53.59%; H, 5.32%; F, 23.02%; N, 11.36%.

Microsomal Metabolism. Flutamide, Flu-1, or Flu-2 (5 μM to 100 μM) were incubated for 1 h at 37°C in an incubation system consisting of 100 mM potassium phosphate buffer (pH 7.4), 2 mg human liver microsomes, 5 mM GSH, and 1 mM NADPH in a final volume of 1 mL. Reactions were terminated by the addition of 6 mL acetonitrile. Samples were mixed on a vortex mixer and centrifuged for 5 min. The supernatants were transferred into conical glass tubes for evaporation to dryness under N₂ at 30°C. The residues were reconstituted in 200 μL of 30:70 (v/v) methanol:20 mM ammonium acetate (pH 4) and aliquots (40 μL) were injected into an HPLC-MS system. Metabolite profiling was performed on an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA) coupled with a Finnigan LCQ-Deca ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Separation was achieved using a kromasil C4 100A column (3.5 μm , 150 x 2.0 mm, Phenomenex, Torrance, CA) at a flow rate of 0.2 mL/min. A gradient of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1%

DMD #20370

formic acid was as follows: initiated with 1% B for 5 min and then increased in a linear manner to 30% at 20 min and to 50% at 25 min, held at 50% until 28 min, changed linearly to 90% at 40 min, maintained at 90% for up to 43 min and then decreased to 1% at 45 min. The column was allowed to equilibrate at 1% solvent B for 5 min prior to the next injection. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 5 min after sample injection. Major operating parameters for the ion-trap ESI-MS method were as follows: capillary temperature 270°C; spray voltage 5.0 kV; capillary voltage -14 V; sheath gas flow rate 90 and auxiliary gas flow rate 30 (arbitrary value). For the detection of Flu-6 GSH adducts the major operating parameters for the ion-trap ESI-MS method were set in the positive mode: capillary temperature 270°C; spray voltage 4.5 kV; capillary voltage 4.5 V; sheath gas flow rate 90 and auxiliary gas flow rate 30. The mass spectrometer was operated with data-dependent scanning. The ions were monitored over a full mass range of m/z 125-1000. For a full scan, the automatic gain control was set at 5.0×10^8 , maximum ion time was 100 ms and the number of microscans was set at 3. For MS^n scanning, the automatic gain control was set at 1.0×10^8 , maximum ion time was 400 ms and the number of microscans was set at 2. For data dependent scanning, the default charge-state was 1, default isolation width was 3.0, normalized collision energy was 45.0.

Flutamide metabolites M5 were isolated from human liver microsomal incubation of flutamide. Further incubation of M5 in human liver microsomes and HPLC-MS analysis were the same as above.

Incubations with cDNA-Expressed Human P450 Enzymes. Flutamide, Flu-1, Flu-6 (50 μ M) were incubated for 1 h at 37 °C in an incubation system consisting of 100 mM potassium phosphate buffer (pH 7.4), recombinant P450 CYP1A2, or CYP3A4, or CYP3A5, or

DMD #20370

CYP2C8, or CYP2C9, or CYP2C19, or CYP2D6 supersomes (50 pmol), 5 mM GSH, and 1 mM NADPH in a final volume of 0.5 mL. After 3-min preincubation, incubations were initiated by the addition of NADPH. Reactions were terminated by the addition of 1 mL acetonitrile. Nilutamide was added as an internal standard. Formation of the glutathionyl adduct was quantified using a Shimadzu LC-10AD VP with binary pumps (Shimadzu, Columbia, MD) coupled with a Q-Trap 4000 (Applies Biosystems/MSD Sciex, Concord, ON, Canada). The adduct was separated by a kromasil C4 100A column (3.5 μ m, 150 x 2.0 mm, Phenomenex, Torrance, CA) at a flow rate of 0.2 mL/min. A gradient of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid was as follows: initiated with 0% B for 3 min and then increased in a linear manner to 90 % at 15 min and then decreased to 0% at 17 min. The column was allowed to equilibrate at 0 % solvent B for 3 min prior to the next injection. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 3 min after sample injection. The Q-trap 4000 electrospray-MS was operated in the negative ionization mode, by applying to the capillary a voltage (IS) of -4.5 kV. Nitrogen was used as curtain gas (CUR), as well as nebulizing (GS1) and turbo spray gas (GS2, heated at 450 °C), with the optimum values set, respectively, at 36, 50, and 40 (arbitrary values). Collisionally activated dissociation (CAD) was performed at 6 (arbitrary value) with nitrogen as collision gas. Declustering potential (DP) was set at -90 V, whereas entrance potential (EP) was set at -10 V; collision energy (CE) was optimized at -34 eV. The multiple reaction monitoring (MRM) transitions used were 596 \rightarrow 323 for G1, 526 \rightarrow 253 for Flu-1-G1, 495 \rightarrow 222 for Flu-1-G2, and 316 \rightarrow 205 for internal standard nilutamide respectively. For Flu-6-G1, the mass spectrometer was operated in a positive ion mode with a capillary voltage of 4.5 kV. The source temperature was set at 450 °C, declustering potential at 65 V, and the entrance

DMD #20370

potential at 10 V. The collision activated dissociation was performed using a collision energy of 40 V. Flu-6-G1 and the internal standard buspirone were monitored in MRM using the transitions of 552→423 for Flu-6-G1 and 386 → 122 for buspirone.

Isolation of GSH Adducts and NMR Characterization. The same human liver microsomal incubation with flutamide was carried out on a 10 mL scale. G1, 2-hydroxyflutamide, M5, and M7 were isolated with the following LC conditions. Separation was achieved using a COSMOSIL 5PYE column (150 x 4.6 mm, Waters, Milford, MA) at a flow rate of 1.0 ml/min with an Agilent 1100 HPLC system (Wilmington, DE). A gradient of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid was as follows: initiated with 100% A for 5 min, changed to 80% A from 5 to 10 min, changed to 50% A from 10 to 60 min, changed to 10% A from 60 to 70 min, held at 10% A from 70 to 75 min, changed to 100% A from 75 to 76 min, and held at 100% A from 76 to 80 min for the column to be equilibrated. All NMR spectra were acquired on a Bruker-Biospin AV700 spectrometer running TopSpin 1.3 software and equipped with a Bruker 5-mm TCI z-gradient Cryoprobe (Bruker, Rheinstetten, Germany). 1D ¹H spectra were acquired with water suppression using a Watergate W5 pulse sequence with gradients and a double echo. 2D COSY and HSQC spectra were acquired without solvent suppression using gradient pulses for coherence selection. Chemical shifts are reported in ppm relative to tetramethylsilane.

Flu-1-G2 was isolated from the incubation of Flu-1 with rat liver microsomes on a 10 mL scale using the method as described above. 1D and 2D NMR spectra were acquired similarly as above.

DMD #20370

Results

In order to assess the bioactivation of flutamide metabolites, the major flutamide metabolites identified in vivo and in vitro were obtained and incubated with human liver microsomes supplemented with NADPH and GSH.

Incubation of 2-Hydroxyflutamide with human liver microsomes. When the major circulating metabolite 2-hydroxyflutamide was incubated in human liver microsomes supplemented with NADPH and GSH, no GSH adducts could be detected.

Formation of GSH Adducts from Flu-1. In the presence of GSH, two GSH adducts were detected in the NADPH-supplemented human liver microsomal incubation of Flu-1 or flutamide (Figure 1). The first GSH adduct (Flu-1-G1) showed a molecular ion at m/z 526 ($[M-H]^-$) in the negative ion mode, 305 Da greater than that of M4, a hydroxylated metabolite of Flu-1 (Scheme 3). Subsequent MS/MS of Flu-1-G1 produced two major fragment ions at m/z of 253 and 272 (Figure 2). The first ion at m/z of 253 was derived from cleavage of sulfur-carbon bond of the glutathionyl moiety and appeared to retain the sulfur atom. The second ion at m/z of 272 was part of glutathionyl moiety and was produced from the same sulfur-carbon bond cleavage. The neutral loss of 129, corresponding to elimination of the pyroglutamate, was also observed in the MS/MS spectrum of Flu-1-G1. The fragmentation pathway suggested that GSH was added to the aromatic ring of M4 (Figure 2).

The second GSH adduct (Flu-1-G2, Figure 1D) from Flu-1 showed a molecular ion at m/z 495 ($[M-H]^-$), an addition of 290 amu to Flu-1 (m/z 205, $[M-H]^-$) which corresponded to the addition of a glutathionyl moiety (307 amu) and loss of the amino group (-17 amu) of Flu-1. MS/MS (Figure 3A) of Flu-1-G2 generated fragment ions at m/z 222 and 272, the latter ion

DMD #20370

being part of the glutathionyl moiety resulted from sulfur-carbon bond cleavage. Further fragmentation of the ion at m/z 222 resulted in the loss of HF and sulfur atom (Figure 3b). The ion at m/z 222 was consistent with substitution of the amino group of Flu-1 by a sulfur atom. Furthermore a change from odd ion of Flu-1 at m/z 205 to an even ion at m/z 222 implicated loss of the amino group. The loss of pyroglutamate (-129 amu) was also observed in MS/MS of Flu-1-G2.

For a more definitive characterization of the structure of Flu-1-G2, the adduct was isolated from the incubation of Flu-1 with human liver microsomes. ^1H NMR spectrum of Flu-1-G2 showed (Figure 4, Table 1) three aromatic proton signals (3, 5, and 6). The presence of a larger J coupling of 9.30 Hz between 5 and 6, a smaller J coupling of 2.36 Hz between 3 and 5, and an undetectable coupling between 3 and 6 is consistent with the aromatic substitution pattern of the proposed structure (Figure 4). This aromatic substitution pattern of Flu-1-G2 was identical to that of flutamide, which strongly suggested replacement of the amino group by a glutathionyl moiety. The proton signals of glutathionyl group appeared in the region from 1.8 ppm to 4.5 ppm in the ^1H -NMR spectrum. The assignments of all the glutathionyl protons were achieved by a ^1H - ^1H COSY experiment (data not shown).

Formation of GSH Adduct G1 from M5. M5 is a minor metabolite and only observed in human liver microsomal incubations. However a closer examination of the NADPH-supplemented human liver microsomal incubations of flutamide with GSH revealed that in addition to the N-glutathionyl flutamide adduct identified in the previous report (Kang et al, 2007), another major GSH adduct (G1) was also formed and it was later shown to be derived from M5.

DMD #20370

G1 displayed a molecular ion of m/z 596 ($[M-H]^-$) in the MS spectrum (Figure 1A, 1B), 305 Da greater than that of a mono-oxygenated metabolite of flutamide. Further fragmentation of G1 molecular ions resulted in a neutral loss of 129, corresponding to elimination of the pyroglutamate of GSH. MS/MS spectrum of G1 showed two intense fragment ions at m/z of 323 and 306 respectively (Figure 5A). The ion at m/z 306 corresponded to the molecular ion of GSH ($[M-H]^-$) as fragmentation of this ion produced diagnostic fragment ions of GSH. The ion at m/z of 323 was formed via cleavage of sulfur-carbon bond of the glutathionyl moiety and still retained the sulfur atom. Further fragmentation of the ion at m/z 323 afforded two ions at m/z of 259 and 205 respectively (Figure 5B), which suggested attachment of the glutathionyl moiety to the isobutyramide instead of the aromatic group.

G1 was isolated from human liver microsomal incubation of flutamide and NMR analyses allowed the definitive assignment of the structure. The corresponding chemical shifts and coupling constants of G1 are shown in Table 1. The presence of glutathionyl moiety in G1 was confirmed by the proton signals in the region from 1.8 to 4.5 ppm. Three aromatic proton signals appeared from 8.0 to 8.3 ppm. Interestingly double peaks appeared for aromatic proton 3 and 6 in 1H NMR spectrum of G1 in methanol- d_4 (supplemental material), indicating that G1 was a mixture of diastereomers due to a newly formed chiral center (carbon g in Figure 5). The proton signals of the two methyl groups of flutamide (d, 6H, 1.22 ppm, $J = 4.85$ Hz) disappeared and two new peaks appeared at 3.74 ppm (d, 2H, $J = 4.85$ Hz) and 2.74 ppm (d, 2H, $J = 5.32$ Hz) respectively, indicating the modification of both methyl groups in G1. The chemical shifts at 3.74 ppm and 2.74 ppm are consistent with literature chemical shifts of hydroxymethyl and thiol methyl respectively (Dean, 1987). The methine hydrogen of flutamide (m, 1H, 2.66 ppm, $J = 6.85$ Hz) shifted down field to 2.92 ppm in G1 (m, 1H, $J = 5.32, 4.85$ Hz). Since the three

DMD #20370

new proton signals of G1 were overlapped with those of glutathionyl moiety, a ^1H - ^1H COSY experiment was conducted to distinguish these mixed signals. As shown in the COSY spectrum of G1 (Figure 6), the peak at 2.92 ppm was coupled to the two peaks at 3.74 ppm and 2.74 ppm respectively whereas the later two peaks were not coupled to each other, thus confirmed the assignment of methine hydrogen at 2.92 ppm. The results of NMR experiments have indicated the presence of a hydroxymethyl and a glutathionyl methyl in G1 structure.

Formation of GSH Adducts from Flu-6. Although Flu-6 was not formed in human liver microsomal incubations of flutamide, it was detected in vivo in human plasma and urine samples (Katchen and Buxbaum 1975, Takashima et al., 2003). This metabolite was synthesized from flutamide by sodium sulfide-mediated reduction of the nitro group. Incubation of Flu-6 in NADPH-supplemented human liver microsomes in the presence of GSH generated three adducts with the same molecular ion at m/z 552 ($[\text{M}+\text{H}]^+$) in positive ion mode: Flu-6-G1, Flu-6-G2, and Flu-6-G3, corresponding to the attachment of a glutathionyl moiety (305 amu) to FLU-6 (Figure 7A). The most abundant of the three was Flu-6-G1. MS/MS of the molecular ions at Flu-6-G1 at m/z 552 mainly afforded an ion at m/z 423 from the loss of pyroglutamate (-129) (Figure 8A). Further fragmentation of this ion yielded fragment ions shown in Figure 8B. A fragmentation pathway of the ion at m/z 423 is proposed (Figure 9). The cyclized structure of the ions at m/z 320 and 303 suggested that the glutathionyl could be attached to the aromatic ring and adjacent to either amino or amide nitrogen. The ion at m/z 277 (30 amu higher than FLU-6 molecular ion) should still retain the sulfur atom. Further fragmentation of the ion at m/z gave rise to an ion at m/z 207 from cleavage of the amide bond and retention of the sulfur atom, consistent with attachment of the glutathionyl group to aromatic ring (Figure 8C). Similar MS spectra were observed for the other two adducts, suggesting the three FLU-6-Gs were

DMD #20370

regio-isomers following attack of GSH on the three unsubstituted positions of the aromatic ring of Flu-6 (Scheme 4).

Incubation of Flu-6 with N-acetyl cysteine methyl ester generated three cysteine conjugates (Flu-6-Cys1, Flu-6-Cys2, and Flu-6-Cys3, Figure 7B) in a similar fashion, all with a molecular ion at m/z 408 ($[M+H]^+$), suggesting addition of acetyl cysteine to Flu-6 and hydrolysis of the methyl ester (Scheme 6). MS/MS of the ion at m/z 408 (Figure 10A) resulted in the same ion at m/z 320 which upon further fragmentation yielded the ion at m/z 303, also present in MS/MS of Flu-6-G1 (Figure 10B). The fragmentation pathway of the ion at m/z 423 of Flu-6-G1 (Figure 9) can be applied to account for the formation of fragment ions of the acetyl cysteine adduct of Flu-6.

Formation of GSH Adducts from Flu-2. Incubation of Flu-2 in human liver microsomes mainly generated Flu-1 via hydrolysis of the amide bond; and Flu-G1 and Flu-G2 were the two GSH adducts formed following further bioactivation of Flu-1 (data not shown).

GSH Adducts Formation by cDNA-Expressed Human P450 Enzymes. The formation of G1, Flu-1-G1, Flu-1-G2, and Flu-6-G1 was found to be NADPH dependant. To examine the possible involvement of P450 isozymes in the formation of these GSH adducts, incubations of flutamide or Flu-1 or Flu-6 in recombinant human P450 isozymes with GSH and NADPH were conducted.

Highest formation of G1 was observed in recombinant CYP1A2 incubation, followed by CYP2C19. G1 was not detectable in CYP3A4, 3A5, 2C8, 2C9, 2D6 incubations (Figure 11A). After normalization of relative hepatic abundance of P450 isozymes (Rodrigues AD 1999), CYP1A2 turned out to be the major isoform responsible for the formation of G1 (94%).

DMD #20370

CYP2C19 played a minor role in the bioactivation pathway leading to the observed adduct (6%). An inhibition study in human liver microsomes with a mechanism-based CYP1A2 specific inhibitor furafylline (25 μ M) resulted in a 99% inhibition of G1 formation, confirming the major role played by CYP1A2.

The formation of Flu-1-G1 showed different dependency on P450 isoforms. As shown in Figure 11B, recombinant CYP2C19 displayed the highest activity. CYP3A4, 1A2, and 2D6 exhibited lower activity toward the formation of Flu-1-G2. After normalization of relative hepatic abundance of P450 isozymes, CYP3A4 accounts for 48% of Flu-1-G2 formation followed by CYP2C19 (28%), and 1A2 (13%).

Studies of Flu-1-G2 formation by recombinant P450s showed that the highest activity was catalyzed by CYP2C8 (Figure 11C). Lower activities were found in CYP1A2, 2C9, 2C19, and 2D6. After normalization of relative hepatic abundance of P450 isozymes, CYP2C8 was the major isoform responsible for the formation of Flu-1-G2 (50%). CYP1A2 (13%) and CYP2C9 (11%) played a minor role in the formation of Flu-1-G2.

Among the recombinant P450 isozymes tested, CYP1A2 was also the most active P450 isozyme catalyzing the formation of Flu-6-G1 (55% after normalization of relative hepatic abundance of P450 isozymes) followed by CYP3A4 (33%). CYP2C19 and CYP2D6 were involved to a lesser extent (Figure 11D).

DMD #20370

Discussion

In a previous study of the bioactivation of flutamide in human liver microsomes, a novel N-S glutathionyl adduct was identified. The present study revealed the formation of several GSH adducts (G1, Flu-1-G1, Flu-1-G2, Flu-6-G1) derived from the metabolites of flutamide in human liver microsomal incubations with of GSH and NADPH.

G1 was the most abundant GSH adduct observed in human liver microsomal incubation of flutamide (Figure 1A). Based on its structure, G1 was unlikely to be the result of direct bioactivation of parent flutamide, instead it can be derived from the hydroxylated metabolite/metabolites of flutamide. However, 2-hydroxyflutamide was not the precursor of G1 as incubation of 2-hydroxyflutamide with human liver microsomes failed to show any detectable G1. We explored the origination of G1 from other oxidative metabolites of flutamide. Monohydroxylated metabolite M5 and dihydroxylated flutamide M7 were isolated and incubation with human liver microsomes was conducted for each isolated metabolite. The incubation of M7 failed to yield any detectable G1. M5 generated significant amounts of G1 in addition to M7 (data not shown). A proposed mechanism for G1 formation from M5 is shown in Scheme 2. Abstraction of the methine hydrogen of M5 by P450 would generate a carbon centered radical **1**, oxygen rebound to the radical results in the formation of M7 (pathway b). Alternatively loss of a hydrogen radical from the methyl group of **1** produces an α , β unsaturated hydroxyflutamide **2** (pathway a), a Michael receptor that can be attacked by GSH to form G1. An interesting feature of ^1H NMR spectrum of G1 in methanol- d_4 is the appearance of double peaks for proton 3 and 6, indicating two diastereomeric GSH conjugates in G1 due to the newly formed chiral center (carbon g), which would be expected when GSH attacks the proposed intermediate **2** in Scheme 2. P450-mediated desaturation is well

DMD #20370

documented in literature (Ortiz de Montellano, 1995). This bioactivation pathway is consistent with the recent finding that a mercapturic acid conjugate of a hydroxylated flutamide was detected in the urine of prostate cancer patients treated with flutamide (Tevell et al., 2006). Although the authors proposed a different structure with a hydroxyl group on the tertiary carbon and a mercapturic acid attached to the primary carbon of the isopropyl group, several common MS fragment ions such as m/z 323, 289, 259, 205 were present in the spectra of both G1 and the mercapturic acid conjugate, suggesting that the mercapturic acid conjugate was a processed product of G1 in vivo via hydrolysis and acetylation. A deglutamyl derivative of G1, an intermediate to the mercapturic acid conjugate, was also observed in human liver microsomal incubation (data not shown). A GSH conjugate of a hydroxylated flutamide has also been reported in other two studies (Soglia et al., 2006; Kostrubsky et al., 2007) which is most likely G1 based on the fact that only one GSH conjugate of the hydroxylated flutamide is generated in human liver microsomal incubations.

Flu-1-G1 is proposed to be derived from Flu-3 as a result of aromatic hydroxylation of Flu-1 followed by oxidation to a quinone imine which is trapped by GSH (Scheme 3, pathways a). Flu-3 is the major metabolite in the urine of prostate cancer patients treated with flutamide; however, it is mainly in the form of sulfate and glucuronic acid conjugate. Although current study showed Flu-3 was bioactivated in human liver microsomes, the extensive phase II conjugation pathways could efficiently remove Flu-3 from the body and limit its bioactivation in vivo. On the other hand the conjugates could potentially transport the reactive metabolite to other organs and cause toxicity locally.

Although the net result of Flu-1-G2 conjugation reaction appeared to be a direct aromatic substitution of the amino group of Flu-1 by GSH, Flu-1-G2 was only formed in

DMD #20370

NADPH-supplemented liver microsomal incubation. A proposed mechanism (Scheme 3, pathway b) involves initial oxidation of Flu-1 to N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine (Flu-1-N-OH) (Goda et al., 2006), which is further oxidized to a nitroso derivative of Flu-1 (Flu-1-N=O). Due to electron-withdrawing effect of the para nitro group, nucleophilic aromatic substitution of the nitroso group by GSH gives rise to Flu-1-G2. The proposed mechanism is supported by a recent report that chemical reaction of nitrosonitrotyrene with GSH yielded a similar adduct via nucleophilic aromatic substitution of the nitroso group (Straube et al, 2005). Nitrosoarenes are reactive intermediates that can react with cellular thiols such as GSH and may play an important role in the biological effects of these compounds. The reaction generally started with formation of a semimercaptal from nucleophilic addition to the nitroso group by GSH. The cleavage of N-O bond generated a cationic sulfenamide intermediate which can be stabilized by electron-donating substituents normally found in the nitrosoarenes in these studies (Gallemann et al., 1994, 1998a, 1998b, Kazanis et al., 1992). Interestingly, the reaction of the proposed Flu-1-N=O did not undergo nucleophilic addition of GSH to the nitroso group since no such GSH adducts were detected, instead it underwent a nucleophilic aromatic substitution of the nitroso group by GSH. A possible explanation could be the failure to stabilize the cationic sulfenamide intermediate due to electron withdrawing effect of the 4-nitro group of Flu-1. The proposed precursor of Flu-1-N=O, Flu-1-N-OH, was recently observed both in vitro and in vivo in human and has been found to be cytotoxic toward rat hepatocytes (Goda et al., 2006). This metabolite was also found to be mainly conjugated in vivo.

Both Flu-1-G1 and Flu-1-G2 were also found in the incubation of parent flutamide with human liver microsomes in the presence of NADPH and GSH. Since flutamide was shown to

DMD #20370

be hydrolyzed to Flu-1 in liver microsomes, the two GSH adducts were most likely formed from subsequent bioactivation of the hydrolyzed metabolite Flu-1. Flu-1-G1 and Flu-1-G2 were also observed in human liver microsomal incubations of oxygenation metabolites (2-hydroxyflutamide, M5, and M7) where the metabolites were hydrolyzed to yield Flu-1 (data not shown).

The proposed mechanism for the formation of Flu-6-G1, Flu-6-G2, and Flu-6-G3 from Flu-6 involves initial oxidation of Flu-6 to a diimine intermediate (Scheme 4, pathway a) and subsequent nucleophilic attacks by GSH or acetyl cysteine methyl ester (Scheme 4, pathway b) at the three unsubstituted positions of the aromatic group. The mechanism is analogous to that recently reported in the formation of amino acid conjugates of 2,5-¹³C-dimethyl-p-benzoquinonediimine (Eilstein et al., 2006). Flu-6 has been detected in human urine and plasma, albeit at a lower level than those of 2-hydroxyflutamide and Flu-1.

The formation of the GSH adducts of flutamide metabolites were NADPH dependent, indicating the involvement of cytochromes P450. CYP1A and CYP3A have been shown to be involved in the covalent binding of flutamide to liver proteins (Berson et al., 1993, Fau et al., 1994). Phenotyping studies indicated that the P450 isozymes involved in the formation G1 and a previously reported *N*-(glutathio-*S*-yl) flutamide adduct are mainly CYP1A2 and CYP2C19. The major involvement of CYP1A2 in the formation of G1 could be due to the predominant role of CYP1A2 in catalyzing the formation of G1 precursor M5. A hydroxyflutamide mercapturic acid conjugate was detected in the urine of prostate cancer patients treated with flutamide (Tevell et al., 2006). Based on the similarity of MS data, this mercapturic acid conjugate is most likely derived from G1. It appears that this CYP1A2 mediated bioactivation pathway exists in vivo. However; low CYP1A2 activity has been associated with the onset of flutamide-

DMD #20370

induced hepatic dysfunction and induced CYP1A2 activity has been thought to be risk-lowering factor in smokers for developing flutamide hepatotoxicity (Nakagawa et al. 1999, Ozono et al., 2002). The role of CYP1A2 in flutamide-induced hepatotoxicity remains uncertain. CYP3A is the other major P450 isozyme responsible for the bioactivation of flutamide and subsequent covalent binding to liver proteins (Berson et. al. 1993). However, there was only a marginal involvement of CYP3A4 in the formation of G1 and *N*-(glutathio-S-yl) flutamide adduct (Kang et al, 2007). CYP3A4 must play a major role in the bioactivation of other flutamide metabolites. Indeed the present study showed that the formation of Flu-1-G1 was mediated by CYP3A4. It has also been reported recently that CYP3A4 is the major P450 isoform catalyzing the formation of Flu-3 and Flu-1-N-OH (Goda et al., 2006), the two proposed precursors of Flu-1-G1 and Flu-1-G2 respectively (Scheme 3), in the liver microsomal incubation of Flu-1. The involvement of CYP2C19 in the bioactivation of flutamide and its metabolite has not been shown in previous studies. Our results suggest further study may be warranted to assess the role of CYP2C19 in catalyzing the bioactivation of flutamide and the associated hepatotoxicity.

A summary of the bioactivation pathways of flutamide and its metabolites and the major P450 isozymes associated with each pathway is shown in Scheme 5. In addition to the one characterized previously for the parent (Kang et al., 2007), we have identified several bioactivation pathways of flutamide metabolites in the present study. These results suggest that, in addition to the direct bioactivation of parent flutamide, flutamide metabolites could contribute to the overall bioactivation of flutamide and potentially cause the flutamide-induced hepatotoxicity.

DMD #20370

References

Aizawa Y, Ikemoto I, Kishimoto K, Wada T, Yamazaki H, Ohishi Y, Kiyota H, Furuta N, Suzuki H, and Ueda M. (2003) Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. *Mol Cell Biochem.* **252**, 149-156.

Asakawa N and Yamashita K (1995) Studies on the metabolic fate of flutamide. *Antibiot Chemother* 11: 1418–1427.

Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D, Maurel P, and Pessayre D (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450 including forms belonging to the 3A and 1A subfamilies. *J. Pharmacol. Exp. Ther.* **265**, 366-372.

Brogden RN and Clissold SP (1989) Flutamide – A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. *Drugs* 38, 185-203.

Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Unluhizarci K. (1999) Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. *Human Exp. Toxicol.* **18**, 137-140.

Dean JA (1987) *Handbook of Organic Chemistry*. McGraw-Hill, New York.

Eilstein J, Gimenez-Arnau E, Duche D, Rousset F, Lepoittevin JP. (2006) Synthesis and reactivity toward nucleophilic amino acids of 2,5-[¹³C]-dimethyl-p-benzoquinonediimine. *Chem Res Toxicol.* **19**, 1248-1256.

DMD #20370

Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D. (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. *J Pharmacol. Exp. Ther.* **269**, 954-962.

Galleman D, Eyer P. (1994) Additional pathways of S-conjugate formation during the interaction of thiols with nitrosoarenes bearing pi-donating substituents. *Environ Health Perspect.* **102**, 137-142.

Galleman D, Greif A, Eyer P, Dasenbrock J, Wimmer E, Sonnenbichler J, Sonnenbichler I, Schafer W, Buhrow I. (1998a) Formation of 4,4-dialkoxycyclohexa-2,5-dienone N-(thiol-S-yl)imine during reaction of 4-alkoxynitrosobenzenes with thiols in alcoholic solvents. *Chem Res Toxicol.* **11**, 1423-1433.

Galleman D, Greif A, Eyer P, Wagner HU, Sonnenbichler J, Sonnenbichler I, Schafer W, Buhrow I. (1998b) Additional pathways of S-conjugate formation during interaction of 4-nitrosophenetole with glutathione. *Chem Res Toxicol.* **11**, 1411-1422.

Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y. (2006) Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. *Drug Metab. Dispos.* **34**, 828-835.

Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, and Labrie F (1992) Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. *Am. J. Med.* **92**, 563-566.

Hart W and Stricker BHC (1989) Flutamide and hepatitis. *Ann. Intern. Med.* **110**, 943-944.

DMD #20370

Ichimura E, Hara K, Matsuzaki Y, and Doi M (1999) Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats. *Acta. Hepatol. Jpn.* **40**, 227-234.

Kang P, Dalvie D, Smith E, Zhou S, Deese A. (2007) Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. *Drug Metab Dispos.* **35**, 1081-1088

Katchen B, and Buxbaum S, (1975) Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. *J. Clin. Endocrinol. Metab.* **41**, 373-379.

Kazanis S, McClelland RA (1992) Electrophilic intermediate in the reaction of glutathione and nitrosoarenes. *J. Am Chem Soc.* **114**, 3052-3059

Kostrubsky SE, Strom SC, Ellis E, Nelson SD, Mutlib AE. (2007) Transport, Metabolism, and Hepatotoxicity of Flutamide, Drug–Drug Interaction with Acetaminophen Involving Phase I and Phase II Metabolites. *Chem. Res. Toxicol.* **20**(10), 1503-1512.

Matsuzaki Y, Nagai D, Ichimura E, Goda R, Tomura A and Doi M (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. *J. Gastroenterol.* **41**, 231-239.

McLeod D. G. (1993) Antiandrogenic drugs. *Cancer* **71**, 1046-1049.

Nakagawa Y, Koyama M, and Matsumoto M (1999) Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. *Acta Urol. Jpn.* **45**, 821-826.

DMD #20370

Ortiz de Montellano PR (1995) Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR eds) pp. 274-276, Plenum Press, New York,

Osculati A and Castiglioni C (2006) Fatal liver complications with flutamide. *Lancet* **367**, 1140-1141.

Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, Yoshida K, Ichinei M, Yamashita T, Hirao Y. (2002) Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. *Prostate Cancer Prostatic Dis.* **5**,128-131.

Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T, Jr. Lin JS, Hagman WK, Evans DC and Kumar S (2003) Addressing the metabolic activation potential of new leads in drug discovery: A case study using ion trap mass spectrometry and tritium labeling technique. *J. Mass Spectrom.* **38**, 211-221.

Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, and Bennett CL. (2001) Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. *Urology* **57**, 727-732.

Schulz M, Schmold A, Donn F and Becker H (1988) The pharmacokinetics of flutamide and its major metabolites. *Eur. J. Clin. Pharmacol.* **34**, 633-636.

Shet M, McPhaul M, Fisher CW, Stallings NR and Eastabrook RW (1997) Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. *Drug Metab. Dispos.* **25**, 1298-1303.

Soglia JR, Contillo LG, Kalgutkar AS, Zhao S, Hop CE, Boyd JG, and Cole MJ (2006) A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro

DMD #20370

utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. *Chem. Res. Toxicol.* **19**, 480-490.

Straube E, Volkel W, Bringmann G, Dekant W. (2005) Reaction of nitroso derivatives of dinitropyrenes with sulfhydryl groups of peptides and hemoglobin in vitro and in rats. *Xenobiotica.* **35**, 1147-1164.

Takashima E, Iguchi K, Usui S, Yamamoto H, Hirano K. (2003) Metabolite profiles of flutamide in serum from patients with flutamide-induced hepatic dysfunction. *Biol Pharm Bull.* **26**, 1455-1460.

Tevell A, Lennernas H, Jonsson M, Norlin M, Lennernas B, Bondesson U, and Hedeland, M (2006) *Drug Metab. Dispos.* **34**, 984-992.

Thole Z, Manso G, Salgueiro E, Revuelta P, and Hidalgo A. (2004) Hepatotoxicity induced by antiandrogens: a review of the literature. *Urol Int*; **73**, 289-295.

Watanabe N, Goda R, Irie T and Yamashita K (2001) In vitro effects of fluoroquinolone antibacterial agents on flutamide metabolism in human liver microsomes. *Jpn. J. Clin. Pharmacol. Ther.* **32**, 65-71.

Wysowski DK and Fourcroy JL. (1996) Flutamide hepatotoxicity. *J Urol.*; 155, 209-212.

DMD #20370

Footnotes.

Part of this work was presented at the 8th International ISSX Meeting, Sendai, Japan, October 9-12, 2007.

1. Current affiliation: Genentech, Inc., South San Francisco, California.

DMD #20370

Legends for Figures

Figure 1. UV and extracted ion chromatograms (XIC) of Flu-1-G1, Flu-1-G2, and G1 in human liver microsomal incubations of flutamide. A) UV chromatogram at 306 nm, B) XIC of G1 at m/z 596 ($[M-H]^-$), C) XIC of Flu-1-G2 at m/z 495 ($[M-H]^-$), D) XIC of Flu-1-G1 at m/z 526 ($[M-H]^-$).

Figure 2. MS/MS spectrum of Flu-1-G1 at m/z 526 ($[M-H]^-$).

Figure 3. (A) MS/MS spectrum of Flu-1-G2 at m/z 495 ($[M-H]^-$). B) MS³ mass spectrum of Flu-1-G2 (the fragment ion at m/z 222) in data-dependent scanning mode on an ion trap mass spectrometer.

Figure 4. ¹H NMR spectrum of Flu-1-G2, the spectrum was acquired on the isolated Flu-1-G2 dissolved in methanol-d₄ with water suppression using a Watergate W5 pulse sequence with gradients and a double echo. The signal of b is not observable due to water suppression.

Figure 5. (A) MS/MS spectrum of flutamide G1, at m/z 596 ($[M-H]^-$). B) MS³ mass spectrum of G1 (the fragment ion at m/z 323) in data-dependent scanning mode on an ion trap mass spectrometer.

Figure 6. Expanded region of the chemical shifts exhibiting the glutathionyl and isopropyl groups in the ¹H-¹H COSY spectrum of G1 in D₂O.

Figure 7. Extracted ion chromatograms (XIC) of Flu-6-Gs at m/z 552 ($[M+H]^+$) (A) and Flu-6 acetyl cysteine adducts at m/z 408 ($[M+H]^+$) (B) in human liver microsomal incubations.

Figure 8. A) MS/MS spectrum of Flu-6-G1 at m/z 552 ($[M+H]^+$), B) MS³ mass spectrum of Flu-6-G1 (the fragment ion at m/z 423), C) MS⁴ mass spectrum of the fragment ion of Flu-6-G1 at m/z 277.




DMD #20370

Figure 9. Proposed fragmentation pathway of Flu-6-G1 fragment at m/z 423.


Figure 10. A) MS/MS spectrum of Flu-6-Cys1 at m/z 408 ($[M+H]^+$), B) MS³ mass spectrum of the fragment ion at m/z 320.

Figure 11. (A) The relative formation of the glutathione conjugate G1 from flutamide mediated by heterologously expressed P450 isoforms. The amounts of G1 produced by CYPs were represented by the ratio of peak areas of G1 to that of internal standard, nilutamide. The CYP-mediated formation of G1 was normalized to CYP1A2. (B) The relative formation of Flu-1-G1 from Flu-1 mediated by heterologously expressed P450 isoforms. The amounts of Flu-1-G1 produced by CYPs were represented by the ratio of peak areas of Flu-1-G1 to that of internal standard, nilutamide. The CYP-mediated formation of Flu-1-G1 was normalized to CYP2C19. (C) The relative formation of Flu-1-G2 from Flu-2 mediated by heterologously expressed P450 isoforms. The amounts of Flu-1-G2 produced by CYPs were represented by the ratio of peak areas of Flu-1-G2 to that of internal standard, nilutamide. The CYP-mediated formation of Flu-1-G2 was normalized to CYP2C8. (D) The relative formation of Flu-6-G1 from Flu-6 mediated by heterologously expressed P450 isoforms. The amounts of Flu-6-G1 produced by CYPs were represented by the ratio of peak areas of Flu-6-G1 to that of internal standard, nilutamide. The CYP-mediated formation of Flu-6-G1 was normalized to CYP1A2.


Table 1. ¹H NMR data for flutamide, G1 and Flu-1-G2 in methanol-d₄

						
	Proton chemical shift (ppm)	J coupling constant (Hz)	Proton chemical shift (ppm)	J coupling constant (Hz)	Proton chemical shift (ppm)	J coupling constant (Hz)
3	8.25	-	8.34	2.30	8.36	2.36
5	8.03	-	8.08	8.93, 2.30	8.33	9.30, 2.36
6	8.03	-	8.04	8.93	7.86	9.30
g	2.66	6.85	2.92	5.32, 4.85		
h	1.22	6.85	2.74	5.32		
i	1.22	6.85	3.74	4.85		


Scheme 1. Metabolic pathways of flutamide, the short names have been used in publications by Aizawa et al. (2003) and Takashima et al. (2003).




Scheme 2. Proposed mechanism for the formation of G1 from flutamide in human liver microsomal incubations supplemented with NADPH and GSH.



Scheme 3. Proposed mechanism for the formation of Flu-1-G1 and Flu-1-G2 from Flu-1 in human liver microsomal incubations supplemented with NADPH and GSH



Scheme 4. Proposed mechanism for the formation of Flu-6-G1, 2, 3 and Flu-6-Cys1, 2, 3 from Flu-6 in human liver microsomal incubations supplemented with NADPH and GSH/ N-acetyl cysteine methyl ester



Scheme 5. Proposed bioactivation pathways of flutamide and its metabolites





Figure 1



Downloaded from dmnd.aspetjournals.org at ASPET Journals on April 18, 2024

Figure 2




Figure 3




Figure 4




Figure 5




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11

